Chief Medical Officer
Title: Chief Medical Officer
Education: PhD, MD and specialist degree in oncology at Karolinska Institute/University hospital.
Background: Pia Baumann has substantial experience in drug development in the cancer field. Her experience comes from many years of clinical work at Karolinska Hospital and larger pharmaceutical companies as well as smaller biotech companies. Pia has developed global product strategies as well as designed and conducted clinical studies in close collaboration with leading clinics. Former Vice President Medical at AstraZeneca. Prior to that leading, global positions in cancer drug development at Takeda, Incyte and ARIAD Pharmaceuticals.
Shares in Medivir: 51,000 ordinary shares.
Warrants in Medivir: 0.
Chief Financial Officer
Title: Chief Financial Officer.
Education: Degree of Bachelor of Science in Accounting and Finance.
Background: Over 20 years of experience in finance. Former CFO at O'Learys Trademark AB. Prior to that, Interim CFO at Rebtel and Head of Business Control at ICA Sverige AB. Before that held leading positions at Scan AB and SkiStar AB. Experience of working in listed-, private equity- and private companies. Board member of PMD Device Solutions AB.
Shares in Medivir: 76,000 ordinary shares.
Warrants in Medivir: 247,500
VP Clinical Development
Title: VP Clinical Development
Education: PhD in Clinical Neuroscience, Karolinska Institutet. MSc in Molecular Biology, Stockholm University.
Background: More than 15 years’ experience of clinical development from large and small pharma such as Sedana Medical, Affibody and Astra Zeneca, as well as from academic innovation platforms. Has led development projects for biologics, small molecules and medical device within several therapeutic areas. More than 20 years’ experience of project- and portfolio management.
Shares in Medivir: 23,320 ordinary shares.
Warrants in Medivir: 65,000.
Chief Executive Officer
Title: Chief Executive Officer
Education: Bachelor of Science in Business Administration
Background: 25 years of experience from pharmaceutical industry spanning global and local responsibilities. Has led product strategy development for late stage compounds preparing for regulatory approval and commercialisation as well as execution of launch for multiple compounds in specialty care. Primary area of focus in the past 10 years in the field of Oncology. Experience also includes interim CEO role for Sedana Medical AB and Director Investor Relations at AstraZeneca.
Shares in Medivir: 107,000 ordinary shares.
Warrants in Medivir: 490,000.
Chief Scientific Officer
Title: Chief Scientific Officer
Education: PhD in Medical Science at Uppsala University
Background: More than 25 years of experience in cancer research. During the last 10 years focused on industrial drug discovery and development projects in oncology. Prior to that he managed an academic research group as principal investigator, and has initiated several innovative scientific projects in cancer biology. He has published more than 50 scientific articles and holds several patents. Adjunct professor at the Medical Faculty of Uppsala University.
Shares in Medivir: 123,908 ordinary shares
Warrants in Medivir: 197,500